Lenalidomide and dexamethasone in treatment of patients with
relapsed and refractory multiple myeloma - analysis of data
from the Czech Myeloma Group Registry of Monoclonal
Gammopathies

J 2019

Lenalidomide and dexamethasone in treatment of patients with relapsed and refractory multiple myeloma - analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies

MAISNAR, V., Z. STEFANIKOVA, I. SPICKA, Luděk POUR, J. MINARIK et. al.

Basic information

Original name

Lenalidomide and dexamethasone in treatment of patients with relapsed and refractory multiple myeloma - analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies

Authors

MAISNAR, V. (203 Czech Republic, guarantor), Z. STEFANIKOVA (703 Slovakia), I. SPICKA (203 Czech Republic), Luděk POUR (203 Czech Republic, belonging to the institution), J. MINARIK (203 Czech Republic), M. FLOCHOVA (203 Czech Republic), J. RADOCHA (203 Czech Republic), E. GREGORA (203 Czech Republic), N. STECOVA (703 Slovakia), T. JELINEK (203 Czech Republic), A. JUNGOVA (203 Czech Republic), E. KRALIKOVA (703 Slovakia), Lucie BROŽOVÁ (203 Czech Republic, belonging to the institution) and R. HAJEK (203 Czech Republic)

Edition

Neoplasma, Bratislava, Slovenská akademie vied, 2019, 0028-2685

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30204 Oncology

Country of publisher

Slovakia

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 1.721

RIV identification code

RIV/00216224:14110/19:00112506

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.4149/neo_2018_180824N644

UT WoS

000491237700020

Keywords in English

lenalidomide; dexamethasone; multiple myeloma; relapse; refractory; cytogenetic aberrations

Abstract

V originále

Lenalidomide (LEN) is an immunomodulator with clinical activity against myeloma cells. Based on the pivotal phase 3 trials MM-009 and MM-010, the combination of lenalidomide and dexamethasone(DEX) was approved for patients with multiple myeloma who received at least one prior therapy. Here, we evaluated LEN/DEX therapy in whole population and subsequently in selected sub-groups of patients with relapsed/refractory multiple myeloma followed in the Monoclonal Gammopathy Registry of the Czech Myeloma Group. 858 patients were treated with LEN/DEX in Czech Republic and Slovakia until end of 2017. The analyzed sub-groups were defined as patients with high-risk cytogenetic aberrations and patients with relapsed and refractory MM. The ORR (response better than PR) in whole group of patients was 46.3% for all lines of therapy, 26.4% for high-risk group and 32.1% for relapsed and refractory group. Overall survivals (OS) in the same sets were as follows: 25.6, 15.7 and 18.5 months respectively, progression free survival (PFS) was 11.2, 6.4 and 9.0 months, respectively. The most common adverse events were hematologic and infectious. In conclusion, we found our results correlated with those in other studies in terms of OS, PFS and also of treatment toxicity.

Citovat

MAISNAR, V., Z. STEFANIKOVA, I. SPICKA, Luděk POUR, J. MINARIK, M. FLOCHOVA, J. RADOCHA, E. GREGORA, N. STECOVA, T. JELINEK, A. JUNGOVA, E. KRALIKOVA, Lucie BROŽOVÁ and R. HAJEK. Lenalidomide and dexamethasone in treatment of patients with relapsed and refractory multiple myeloma - analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies. Neoplasma. Bratislava: Slovenská akademie vied, 2019, vol. 66, No 3, p. 499-505. ISSN 0028-2685. Available from: https://dx.doi.org/10.4149/neo_2018_180824N644.

@article{1605477,
   author = {Maisnar, V. and Stefanikova, Z. and Spicka, I. and Pour, Luděk and Minarik, J. and Flochova, M. and Radocha, J. and Gregora, E. and Stecova, N. and Jelinek, T. and Jungova, A. and Kralikova, E. and Brožová, Lucie and Hajek, R.},
   article_location = {Bratislava},
   article_number = {3},
   doi = {http://dx.doi.org/10.4149/neo_2018_180824N644},
   keywords = {lenalidomide; dexamethasone; multiple myeloma; relapse; refractory; cytogenetic aberrations},
   language = {eng},
   issn = {0028-2685},
   journal = {Neoplasma},
   title = {Lenalidomide and dexamethasone in treatment of patients with relapsed and refractory multiple myeloma - analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies},
   url = {http://dx.doi.org/10.4149/neo_2018_180824N644},
   volume = {66},
   year = {2019}
}

TY  - JOUR
ID  - 1605477
AU  - Maisnar, V. - Stefanikova, Z. - Spicka, I. - Pour, Luděk - Minarik, J. - Flochova, M. - Radocha, J. - Gregora, E. - Stecova, N. - Jelinek, T. - Jungova, A. - Kralikova, E. - Brožová, Lucie - Hajek, R.
PY  - 2019
TI  - Lenalidomide and dexamethasone in treatment of patients with relapsed and refractory multiple myeloma - analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies
JF  - Neoplasma
VL  - 66
IS  - 3
SP  - 499-505
EP  - 499-505
PB  - Slovenská akademie vied
SN  - 00282685
KW  - lenalidomide
KW  - dexamethasone
KW  - multiple myeloma
KW  - relapse
KW  - refractory
KW  - cytogenetic aberrations
UR  - http://dx.doi.org/10.4149/neo_2018_180824N644
L2  - http://dx.doi.org/10.4149/neo_2018_180824N644
N2  - Lenalidomide (LEN) is an immunomodulator with clinical activity against myeloma cells. Based on the pivotal phase 3 trials MM-009 and MM-010, the combination of lenalidomide and dexamethasone(DEX) was approved for patients with multiple myeloma who received at least one prior therapy. Here, we evaluated LEN/DEX therapy in whole population and subsequently in selected sub-groups of patients with relapsed/refractory multiple myeloma followed in the Monoclonal Gammopathy Registry of the Czech Myeloma Group. 858 patients were treated with LEN/DEX in Czech Republic and Slovakia until end of 2017. The analyzed sub-groups were defined as patients with high-risk cytogenetic aberrations and patients with relapsed and refractory MM. The ORR (response better than PR) in whole group of patients was 46.3% for all lines of therapy, 26.4% for high-risk group and 32.1% for relapsed and refractory group. Overall survivals (OS) in the same sets were as follows: 25.6, 15.7 and 18.5 months respectively, progression free survival (PFS) was 11.2, 6.4 and 9.0 months, respectively. The most common adverse events were hematologic and infectious. In conclusion, we found our results correlated with those in other studies in terms of OS, PFS and also of treatment toxicity.
ER  -

MAISNAR, V., Z. STEFANIKOVA, I. SPICKA, Luděk POUR, J. MINARIK, M. FLOCHOVA, J. RADOCHA, E. GREGORA, N. STECOVA, T. JELINEK, A. JUNGOVA, E. KRALIKOVA, Lucie BROŽOVÁ and R. HAJEK. Lenalidomide and dexamethasone in treatment of patients with relapsed and refractory multiple myeloma - analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies. \textit{Neoplasma}. Bratislava: Slovenská akademie vied, 2019, vol.~66, No~3, p.~499-505. ISSN~0028-2685. Available from: https://dx.doi.org/10.4149/neo\_{}2018\_{}180824N644.

Detailed Information on Publication Record